Release Date: February 26, 2025
Expiration Date: February 26, 2026
Activity Overview
In recent years, a variety of novel biomarker-driven treatment options have emerged for the management of advanced esophagogastric adenocarcinomas, with rapid advances in making the best use of immunotherapies and targeted agents. Moreover, there are new developments in the use of immunotherapy for patients with both early-stage and metastatic disease. This program will bring together world experts in the management of esophagogastric cancer to discuss new and emerging treatment principles for these cancers, presented in the context of challenging case scenarios.
This educational activity is an archive of the live symposium held on January 24, 2025.
Target Audience
This educational program is directed toward medical oncologists, pathologists, surgical oncologists, and other physicians involved in the management of gastrointestinal cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze data evaluating immunotherapy in the management of early- to late-stage gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma
- Examine emerging clinical data on immunotherapy-based treatment strategies in the context of current treatment paradigms for gastric, GEJ, and esophageal adenocarcinoma.
- Select appropriate treatment for a patient with gastric, GEJ, or esophageal adenocarcinoma based on patient-, molecular testing-, disease-, and treatment-related factors.
- Identify strategies to mitigate and manage treatment-related adverse events in patients with gastric, GEJ, or esophageal adenocarcinoma.
Zev A. Wainberg, MD
Professor of Medicine
Co-Director, GI Oncology Program
Director, Early Phase Clinical Research Program
UCLA School of Medicine
Los Angeles, CA
Disclosures: Grant/Research Support: Amgen, Array BioPharma/Pfizer, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Five Prime, Gilead Sciences, Ipsen, Merck, Molecular Templates, Roche/Genentech; Consultant: Amgen, Arcus Biosciences, Array BioPharma, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Ipsen, Merck, Molecular Templates; Honoraria: Amgen, Arcus Biosciences, Alligator Bioscience, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Gilead Sciences, Ipsen, Merck, Roche/Genentech, Janssen, Regeneron.
Manish A. Shah, MD, FASCO
Professor of Medicine
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY
Disclosures: Grant/Research Support: Bristol Myers Squibb, Merck, Oncolys BioPharma.
Syma Iqbal, MD
Associate Professor of Clinical Medicine
Medical Director, Inpatient Services, Norris Cancer Hospital
Medical Director for Ambulatory Services/Infusion Center
Associate Cancer Physician in Chief
Keck School of Medicine
University of Southern California
Los Angeles, CA
Disclosures: Consultant: AstraZeneca, Beigene, Bristol Myers Squibb, Exelixis, Jazz, Merck; Speakers’ Bureau: Astellas.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
